Skip to main content

Drug Interactions between imatinib and oteseconazole

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

imatinib oteseconazole

Applies to: imatinib and oteseconazole

ADJUST DOSE: Coadministration with oteseconazole may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP), which may increase the risk of adverse effects associated with these drugs. The proposed mechanism is decreased clearance due to inhibition of BCRP-mediated intestinal and/or hepatic transport by oteseconazole. When administered with rosuvastatin, a BCRP substrate, oteseconazole increased rosuvastatin peak plasma concentration (Cmax) and systemic exposure (AUC 0-24h) by 118% and 114%, respectively.

MANAGEMENT: When concomitant use of oteseconazole is required, the lowest possible starting dosage or a reduction of the existing dosage of BCRP substrates should be considered. The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a BCRP inhibitor like oteseconazole and for any dosage adjustments that may be required. Patients should be closely monitored for clinical response and adverse effects, and the dosage(s) of concomitant medication(s) further adjusted as necessary.

References

  1. (2022) "Product Information. Vivjoa (oteseconazole)." Mycovia Pharmaceuticals, Inc.

Switch to consumer interaction data

Drug and food interactions

Moderate

imatinib food

Applies to: imatinib

GENERALLY AVOID: Coadministration of imatinib with strong CYP450 3A4 inhibitors such as grapefruit juice, may significantly increase the plasma concentrations of imatinib, a known substrate of CYP450 3A4. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of imatinib by certain compounds present in grapefruits. Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability). In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict. In a single-dose study, coadministration of imatinib with ketoconazole (a strong CYP450 3A4 inhibitor) increased imatinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 26% and 40%, respectively.

MANAGEMENT: Patients treated with imatinib should preferably avoid the consumption of grapefruit or grapefruit juice. If coadministration is unavoidable, monitor for prolonged and/or increased pharmacologic effects of imatinib, including edema, hematologic toxicity and immunosuppression.

References

  1. (2022) "Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. Cerner Multum, Inc. "Australian Product Information."

Switch to consumer interaction data

Moderate

oteseconazole food

Applies to: oteseconazole

ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of oteseconazole. When administered with a high-fat, high-calorie meal (800 to 1000 calories; 50% fat), oteseconazole peak plasma concentration (Cmax) and systemic exposure (AUC 0-72h) increased by 45% and 36%, respectively. However, no significant differences were observed with a low-fat, low-calorie meal.

MANAGEMENT: Oteseconazole should be administered with food.

References

  1. (2022) "Product Information. Vivjoa (oteseconazole)." Mycovia Pharmaceuticals, Inc.

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer